Nektar is not alone in this space and other TLR7/8 agonists have shown real promise as intratumoral therapies. The other Nektar agent is the modified IL-2 that looks like it may confer some benefit on top of PD-1. So, in all, this trial is about as good a trial to consider in the PD1 + X category.”
Viewing 1 post (of 1 total)
The forum ‘Clinical Trials for Melanoma’ is closed to new topics and replies.